(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 28.95% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Guardant Health's revenue in 2026 is $1,183,105,000.On average, 32 Wall Street analysts forecast GH's revenue for 2026 to be $187,606,245,660, with the lowest GH revenue forecast at $177,273,140,570, and the highest GH revenue forecast at $193,242,484,800. On average, 32 Wall Street analysts forecast GH's revenue for 2027 to be $254,167,545,980, with the lowest GH revenue forecast at $225,986,350,280, and the highest GH revenue forecast at $293,487,023,790.
In 2028, GH is forecast to generate $345,286,745,410 in revenue, with the lowest revenue forecast at $286,911,411,460 and the highest revenue forecast at $444,591,911,210.